Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study
Research output: Contribution to journal › Journal article › Research › peer-review
The use of positron emitter-labeled compounds for somatostatin receptor imaging (SRI) has become attractive because of the prospect of improved spatial resolution, accelerated imaging procedures, and the ability to quantify tissue radioactivity concentrations. This paper provides results from first-in-humans use of (64)Cu-DOTATATE, an avidly binding somatostatin receptor ligand linked to a radioisotope with intermediate half-life and favorable positron energy (half-life, 12.7 h; maximum positron energy, 0.653 MeV).
|Journal||Journal of Nuclear Medicine|
|Number of pages||9|
|Publication status||Published - Aug 2012|
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Neuroendocrine Tumors, Octreotide, Organometallic Compounds, Positron-Emission Tomography, Quality Control, Radiation Dosage, Radiochemistry, Tomography, Emission-Computed, Single-Photon